Skip to content

An exploratory study on the efficacy of benvimoder cream in the treatment of onychopsoriasis

An exploratory study on the efficacy of benvimoder cream in the treatment of onychopsoriasis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047728
Enrollment
Unknown
Registered
2021-06-23
Start date
2021-02-01
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis of nail

Interventions

Self control:Benvimoder cream for external use on test side versus Control side external use of halomisone cream

Sponsors

Beijing You'an Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Chinese adult patients aged 18-65 years with psoriasis, including male and female; 2) The manifestations of nail bed and / or parent material involvement were consistent with those of psoriasis (nail bed: oil drop like change, nail separation, subungual hyperkeratosis, and linear hemorrhage of nail; nail bed: oil drop like change, nail separation, subungual hyperkeratosis, and linear hemorrhage of nail); Nail parent material: thimble like depression, nail thickening and nail crispness, white nail, crescent shaped bleeding point); 3) Those who did not receive local or systemic treatment at least 4 weeks before the baseline visit and were able to take medication according to the doctor's advice and return visit regularly; 4) Before the baseline visit, fungal and / or new direct mycological examination and culture were negative; 5) Blood and urine routine, liver and kidney function and electrocardiogram were in normal range; 6) Sign informed consent and image authorization.

Exclusion criteria

Exclusion criteria: 1) Received local or systemic treatment for psoriasis within four weeks before baseline visit; 2) Direct mycological examination and culture of fungi and / or bacteria were positive; 3) Pustular or erythrodermic psoriasis; 4) Pregnant and lactating women; 5) Severe hepatic and renal insufficiency; 6) Those who used other drugs that affected the efficacy of the study before the baseline visit; 7) Other situations that the researchers think should not be included.

Design outcomes

Primary

MeasureTime frame
Nail psoriasis severity index (napsi) score;Napsi score;

Countries

China

Contacts

Public ContactZhenzhen Yan
dryanzhenz@163.com+86 18510025779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026